Viewing nowCombinationYumeron Tablet 20/5mg
Olmesartan Medoxomil 20mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.

MFDS item code 202003955 · Approved 2020.05.28
Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerosis progression and cardiovascular disease risk
This medication is prescribed only for patients who must take Olmesartan Medoxomil for hypertension treatment and Rosuvastatin for dyslipidemia treatment simultaneously. Olmesartan Medoxomil helps effectively treat essential hypertension. Rosuvastatin is primarily used as an adjunct to dietary therapy for patients with primary hypercholesterolemia and mixed dyslipidemia, lowering LDL cholesterol levels and delaying atherosclerosis progression. Additionally, it is used as an adjunct in the treatment of familial hypercholesterolemia or dysbetalipoproteinemia. For patients at high risk of cardiovascular events, it helps reduce the risks associated with stroke, myocardial infarction, and vascular revascularization. Therefore, this medication is used to improve cardiovascular health by managing both hypertension and dyslipidemia simultaneously.
This medicine is for adults only. The dose should be individualized for each patient based on the effects and tolerability of each component, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10 mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, the dose may be increased to 20 mg once daily. If further blood pressure reduction is required, the dose may be increased to a maximum of 40 mg once daily. The blood pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum after approximately 8 weeks. If blood pressure is not controlled with this medicine alone, it may be administered concomitantly with a thiazide diuretic such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). In patients who may have intravascular volume depletion (e.g., patients receiving diuretics, especially those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. 2. Elderly patients No dose adjustment is required when this medicine is administered to elderly patients aged 65 years or older. No overall differences in efficacy or safety have been observed between elderly and younger patients; however, the possibility of a more sensitive response in some elderly patients cannot be ruled out. 3. Patients with renal impairment The maximum dose for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20 mg once daily. 4. Patients with hepatic impairment No dose adjustment is required for patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10 mg once daily, and the dose may be increased to a maximum of 20 mg once daily. Use in patients with severe hepatic impairment is not recommended because there is no experience with its use in these patients. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate according to LDL cholesterol levels, the treatment goal, and the patient's response, at intervals of 4 weeks or longer; the dose may be increased to a maximum of 20 mg once daily. 2. Elderly patients No dose adjustment is required. 3. Patients with renal impairment No dose adjustment is required for patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients. Patients taking olmesartan medoxomil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.
The safety and efficacy in children under 18 years of age have not been established.
This medication can severely harm the fetus or newborn if taken during pregnancy, especially in the second and third trimesters, so it must be stopped immediately upon confirmation of pregnancy. Patients with allergies to any of the ingredients of this medication or alcohol intolerance, pregnant or potentially pregnant women, and nursing mothers should not take this medication. It is not safe for patients with severely impaired kidney function or on dialysis, severe liver dysfunction, bile duct obstruction, undiagnosed liver diseases, or muscular diseases to use this medication. Patients with a history of muscle-related diseases, alcohol abuse, the elderly, or specific genetic muscle disorders should exercise caution, as the risk of muscle injury increases with high doses. This medication contains lactose, so it should not be administered to patients with lactose intolerance or related genetic disorders. When initiating this medication in patients with reduced blood volume or low salt levels, hypotension may occur, thus careful monitoring is required. In patients whose kidney function is dependent on this medication or those with renovascular hypertension, it should be administered cautiously, with regular testing of potassium levels and kidney function through blood tests. Since this medication lowers blood pressure, dizziness may occur; therefore, it is advisable to avoid hazardous tasks such as working at heights or driving. Patients with a history of liver disease or excessive alcohol consumption are recommended to undergo liver function tests before and during the administration of this medication. If symptoms such as muscle pain, weakness, or spasms occur, notify medical personnel immediately, and necessary blood tests should be performed to check for muscle damage. When taking this medication with certain drugs (potassium-sparing diuretics, lithium, non-steroidal anti-inflammatory drugs, etc.), the risk of side effects may increase due to interactions, so consultation with healthcare providers is necessary. Women who are pregnant or planning to become pregnant must consult their healthcare provider before taking this medication and employ appropriate contraception. Nursing mothers should consider stopping breastfeeding or discontinuing the medication due to potential adverse effects on the infant. Safety and efficacy have not been established for children under 18 years of age, so use is not recommended. Elderly patients may require dose adjustment due to potential increased drug concentration. In case of overdose, symptoms may include hypotension and palpitations, and appropriate medical treatment should be sought if necessary. This medication should be kept out of reach of children, and it should not be transferred to another container.
Elevation of ALT, elevation of AST, increase in blood creatinine, decrease in creatinine clearance, headache, dizziness, decreased sensation, neuropathy, drowsiness, gastroesophageal reflux disease, constipation, dental caries, dyspepsia, gastric ulcer, gastritis, gastroenteritis, musculoskeletal rigidity, atrial fibrillation, hypoglycemia, chest pain, tooth extraction, chest discomfort, peripheral edema, vertigo, abdominal pain, nausea, palpitations, hypercholesterolemia, hyperlipidemia, hyperuricemia, arthralgia, arthritis, myalgia, rash, asthenia, angioedema, anaphylactic reaction, vomiting, chronic malabsorption, intestinal vascular edema, rhabdomyolysis, hyperkalemia, acute renal failure, hair loss, pruritus, urticaria, autoimmune hepatitis, dizziness (including positional vertigo), palpitations, elevated blood pressure, facial edema, low back pain, increased serum creatinine, diarrhea, chest pain, cough, epistaxis, upper respiratory infection, asthma, hypersensitivity reactions including angioedema, diabetes, headache, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal hepatic failure, cognitive impairment, severe muscle weakness, ocular myasthenia.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container, protected from air and moisture. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius. This storage method helps preserve the efficacy of the medication and prevent degradation.
White or pale yellow round film-coated tablet
30 tablets/box [30 tablets (10 tablets/Alu-Alu) ×3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationOlmesartan Medoxomil 20mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 5.2mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 10mg
Tablet · Prescription medication · Combination
(Co., Ltd. Daewoong Pharmaceutical)
CombinationRosuvastatin Calcium 5.2mg · Olmesartan Medoxomil 10mg
Tablet · Prescription medication · Combination
(Co., Ltd.) Daewoong Pharmaceutical
CombinationRosuvastatin Calcium 10.4mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Daewoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.